C-LA Europe Limited

Endorse Company

CLA Europe is a commercial project to produce pharmaceutical products that are in increasing, world-wide demand. The primary products are safety syringes.

‘The World Health Organization (WHO) estimates that every year unsafe injections result in 80,000-160,000 new HIV-1 infections, 8-16 million hepatitis B infections, and 2•3-4•7 million hepatitis C infections worldwide’. Source: Reeler AV. Injections: a fatal attraction. Soc Sci Med 1990; 31: 1119-25.

The global demand is of immense scope. The ramifications of not progressing to safer methods of injection are monumental: Conservative estimates suggest that in the year 2000 alone, contaminated injections caused about 260,000 new HIV infections, 21 million Hepatitis B infections and 2 million Hepatitis C infections - and recent research published in the International Journal of STD and AIDS argued that up to half of all new HIV infections may be a result of unsafe injections. Many experts agree that this problem can be solved inexpensively.

For an estimated annual cost of less than one percent of the total $15 billion HIV/AIDS package recently approved by U.S. Government, the entire continent of Africa could be supplied with safe injection devices. Doing so would effectively eliminate this entire category of disease spread, according to another WHO report.

Products